The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

Abstract Background Gefitinib, as the first epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC), has been proved to significantly improve the progression-free survival (PFS) in the first-line setting but suf...

Full description

Bibliographic Details
Main Authors: Zhonghan Zhang, Fan Luo, Yang Zhang, Yuxiang Ma, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang, Hongyun Zhao
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Cancer Communications
Subjects:
NSCLC
EGFR
VEGFR
Tyrosine kinase inhibitors
Apatinib
Gefitinib
Online Access:http://link.springer.com/article/10.1186/s40880-019-0414-4

Internet

http://link.springer.com/article/10.1186/s40880-019-0414-4

Similar Items